唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松的临床疗效研究

被引：11

作者：

韩瑞旸 ^{[1
]}

武子朝 ^{[2
]}

刘少军 ^{[1
]}

王微慎 ^{[1
]}

李涛 ^{[1
]}

曹玮 ^{[3
]}

杜随勇 ^{[1
]}

贾宗海 ^{[1
]}

张惠丽 ^{[1
]}

李润根 ^{[1
]}

机构：

[1] 兵器工业五二一医院脊柱外科

[2] 西安市安康医院放射科

[3] 第四军医大学唐都医院介入放射科

来源：

现代生物医学进展 | 2015年 / 15卷 / 01期

关键词：

唑来膦酸; 钙尔奇D; 糖尿病性骨质疏松; 临床疗效;

D O I：

10.13241/j.cnki.pmb.2015.01.025

中图分类号：

R580 []; R587.1 [糖尿病];

学科分类号：

100201 [内科学];

摘要：

目的:观察唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松症的临床疗效。方法:将120例糖尿病性骨质疏松患者随机分为实验组和对照组,实验组60例予唑来膦酸联合钙尔奇D治疗,对照组60例予钙尔奇D治疗。连续治疗12个月后,比较两组患者的骨密度、疼痛评分及不良反应的发生情况。结果:治疗12个月后,实验组患者的股骨颈、股骨粗隆和腰椎正位的骨密度均较对照组明显升高,差异有统计学意义(P<0.05);VAS疼痛评分较对照组显著降低(P<0.05)。治疗过程中,两组均无严重的不良反应发生。结论:唑来膦酸联合钙尔奇D治疗糖尿病性骨质疏松临床效果优于钙尔奇D单药治疗。

引用

页码：104 / 106

页数：3

共 12 条

[1]

Care of the Cholestatic Patient.[J].Andrea A. Gossard.Clinics in Liver Disease.2013,

[2]

Diabetes and bone health [J].

Antonopoulou, Marianna ;

Bahtiyar, Guel ;

Banerji, Mary Ann ;

Sacerdote, Alan S. .

MATURITAS, 2013, 76 (03) :253-259

[3]

Osteoporosis Diagnosis and Medical Treatment [J].

Warriner, Amy H. ;

Saag, Kenneth G. .

ORTHOPEDIC CLINICS OF NORTH AMERICA, 2013, 44 (02) :125-+

[4]

Impact of diabetes and its treatments on skeletal diseases [J].

Yan, Wenbo ;

Li, Xin .

FRONTIERS OF MEDICINE, 2013, 7 (01) :81-90

[5]

Pharmacokinetic evaluation of zoledronic acid [J].

De Luca, Antonella ;

Lamura, Luana ;

Gallo, Marianna ;

Daniele, Gennaro ;

D'Alessio, Amelia ;

Giordano, Pasqualina ;

Maiello, Monica Rosaria ;

Pergameno, Maria ;

Perrone, Francesco ;

Normanno, Nicola .

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (07) :911-918

[6]

Managing bone health with zoledronic acid: a review of randomized clinical study results [J].

Hadji, P. .

CLIMACTERIC, 2011, 14 (03) :321-332

[7]

Zoledronic acid for prevention and treatment of osteoporosis [J].

Recknor, Chris .

EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (05) :807-815

[8]

Role of zoledronic acid in the prevention and treatment of osteoporosis.[J].Louis-Georges Ste-Marie;Louis-Georges Ste-Marie;Andree Boucher;Ages Rakel.Clinical Interventions in Aging.2011, defa

[9]

The role of zoledronic acid in the management of osteoporosis [J].

Maricic, Michael .

CLINICAL RHEUMATOLOGY, 2010, 29 (10) :1079-1084

[10]

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy [J].

Russell, R. G. G. ;

Watts, N. B. ;

Ebetino, F. H. ;

Rogers, M. J. .

OSTEOPOROSIS INTERNATIONAL, 2008, 19 (06) :733-759

← 1 2 →